1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

EuroPCR 2018: Robocath Eyes December CE Mark For R-One Positive Pre-Clin Data

 
• By Tina Tan

Robocath is planning a year-end market launch of its flagship R-One robotic catheterization system after the preclinical trial of R-One hit all primary endpoints. If the product is CE-marked in December as anticipated, it will be a rival to Corindus Vascular's CorPath, which is currently the only robotic-assisted system in the market for interventional cardiology. Robocath announced the preclinical data at EuroPCR in Paris, being held this week until May 25.

Robocath
• Source: Source: Robocath

Robocath's R-One system is expected to be the second robot-assisted system on the market designed specifically for interventional cardiology procedures, as the company plans on getting a CE mark and hitting the European and Middle Eastern markets by the end of the year. The launch comes on the back of positive data from a preclinical study – announced May 22 at this year's EuroPCR meeting in Paris – which showed that the technology met all its primary efficacy and safety endpoints.

The French firm first unveiled R-One at last year's EuroPCR, where it announced it had raised €4.7m from various investors to fund studies of the system.(Also see "EuroPCR 2017:...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By Shubham Singh

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.

More from Device Area

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.